CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
异基因造血细胞移植作为细胞免疫治疗的范式
英文原题：Allogeneic Hemopoietic Cell Transplantation as a Paradigm for Cellular Immunotherapy.
查看英文原题
Allogeneic Hemopoietic Cell Transplantation as a Paradigm for Cellular Immunotherapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究思路按摘要原文分段
背景
异基因造血细胞移植（alloHCT）是血液系统恶性肿瘤及其他严重血液疾病已确立的治愈性治疗手段。然而，alloHCT也以其显著的副作用而闻名。概要：本文综述了靶向分子治疗、免疫治疗、感染学及诊断学方面的最新进展，这些进展提高了alloHCT的耐受性和疗效，将其应用扩展至体能状态较差及老年患者。我们分析了预处理方案、供者选择以及移植物抗宿主病（GVHD）和感染管理方面的进展，并讨论了移植后预防复发的策略。关键信息：从一个全新的视角来看，alloHCT可以作为增强新兴靶向治疗和免疫治疗潜力的平台。
展开英文摘要原文
BACKGROUND: Allogeneic hematopoietic cell transplantation (alloHCT) is an established curative treatment for hematological malignancies and other severe blood disorders. However, alloHCT is also known for its significant side effects. SUMMARY: Here we review recent advances in targeted molecular therapy, immunotherapy, infectiology, and diagnostics that have enhanced the tolerability and efficacy of alloHCT, expanding its use to less fit and elderly patients. We analyze developments in conditioning regimens, donor selection, and the management of graft versus host disease (GVHD) and infections and discuss posttransplantation strategies to prevent relapse. KEY MESSAGE: In a fresh perspective, alloHCT can serve as a platform to enhance the potential of emerging targeted and immune therapies.
论文信息
- 作者
- Weiss-Haug AV、Haraszti RA、Hug S、Faul C、Bethge WA、Lengerke C
- 单位
- Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tuebingen, Tuebingen, Germany.Germany
- 文献类型
- 综述
- 期刊
- Oncology research and treatment2025
- 原文标识
- PubMed 39907999 · DOI 10.1159/000543928